

2018 EMERGING THERAPIES FOR PBC, NASH ESLD AND HCC SEMINAR SERIES

San Diego, CA – May 19, 2018

Conference Location **San Diego Marriott - Del Mar** **Phone: (858)-523-1700**
 119166 El Camino Real,
 San Diego, California, 92130 <http://www.marriott.com/hotels/travel/sandm-san-diego-marriott-del-mar>

Parking at the Conference A reduced parking rate of \$10 for the day has been arranged for all seminar participants. Please bring your ticket to the Seminar Registration Desk for validation.

Driving Directions

From Interstate 5 - Northbound - Take Carmel Valley Road Exit, turn right, turn left onto El Camino Real. Hotel will be on the right side.

From Interstate 5 - Southbound - Take Carmel Valley Road Exit, turn left, turn left again onto El Camino Real. Hotel will be on the right side

Seminar Agenda and Syllabus Information

Registration and breakfast begin at **7:30 a.m.** in the **Grand Ballroom**. Please check signage for any last minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.

| | |
|-----------------|---|
| 7:30 am | Registration, Continental Breakfast & View Exhibits |
| 8:00am | Welcome and Pre-Test |
| 8:20 am | <p>End Stage Liver Disease: Treatment, Managing Complications and Transplant</p> <ul style="list-style-type: none"> • Staging, workup, and diagnosis of cirrhosis • Medical care of the patient with end stage liver disease <p>Liver Transplantation</p> <ul style="list-style-type: none"> • Listing Criteria and MELD Exceptions <p>Case Study 1 – Cirrhosis and Encephalopathy</p> |
| 9:20 am | <p>Hepatocellular Carcinoma</p> <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery |
| 10:00 am | Break & View Exhibits |
| 10:15 am | <p>Hepatocellular Carcinoma: New Systemic Treatment Options</p> <ul style="list-style-type: none"> • Currently FDA Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC <p>Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma</p> |
| 11:00 am | <p>Primary Sclerosing Cholangitis (PSC)</p> <ul style="list-style-type: none"> • Epidemiology • Ursodiol and Antibiotic Treatments |

| | |
|-----------------|--|
| | <ul style="list-style-type: none"> • Predicting Outcomes and Improving Survival |
| 11:40 am | New Treatments for PBC <ul style="list-style-type: none"> • Causes and Markers of PBC • Treatment Management • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid Case Study 3 - PBC with inadequate response to Ursodiol |
| 12:00 pm | Lunch & View Exhibits |
| 12:30 pm | The Best Use of Non-Invasive Imaging for Fibrosis Assessment <ul style="list-style-type: none"> • Technologies, Procedures and Outcomes |
| 1:00 pm | NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology and Demographics • Diagnosis and Evaluation • Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Causing Adult Fatty Liver • Conventional treatments |
| 1:45 pm | Break & View Exhibits |
| 2:00 pm | NASH Treatments in Development <ul style="list-style-type: none"> • Life Style Changes • Drugs in Clinical development for NASH Case Study 4 - NASH Diagnosis and Treatment |
| 3:00pm | Post-test |
| 3:15 pm | Adjourn |

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.2 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1017. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

**Your Seminar
Faculty**



CATHERINE FRENETTE, MD

Dr. Carrie Frenette is the Medical Director of Liver Transplantation in the Department of Organ Transplantation at Scripps Green Hospital, San Diego, CA. She also serves as the Director, Hepatocellular Carcinoma Program for Scripps. She received his bachelor's degree in Biology from Loyola University in Chicago, IL and her medical degree from Rush Medical College, also in Chicago. Dr. Frenette is widely published in many peer-reviewed journals.

Dr. Frenette is active in many professional societies including: the American Gastroenterology Association; American College of Gastroenterology; European Association for the Study of the Liver; The Transplantation Society; the International Liver Cancer Association and the American Liver Foundation.



ROHIT LOOMBA MD, MHSci

Rohit Loomba M.D., MHSci, is Professor of Medicine (with tenure) in the Division of Gastroenterology, and Adjunct Professor in the Division of Epidemiology at University of California at San Diego (UCSD).

He is an internationally recognized expert in translational research and innovative clinical trial design in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), and non-invasive assessment of steatosis and fibrosis using advanced imaging modalities. Dr. Loomba is the founding director of the NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, clinical trial design epidemiology, imaging end-points, and integrated OMICs.



YUKI ROSENKOETTER, PA-C, MPAS

Yuki Rosenkoetter is a Hepatology Physician Assistant in the Division of Gastroenterology and Hepatology at Scripps Clinic Torrey Pines in La Jolla, California.

Ms. Rosenkoetter received her Master in Physician Assistant Studies from the University of Utah School of Medicine's Physician Assistant Program. She has been actively involved in both GI and Hepatology care since 2004 having held positions at the University of Utah School of Medicine, Hawaii Gastroenterology Specialists on Oahu, Hawaii and then assuming her current role at Scripps in 2014.
